Cipla, Sun Pharma, Dr Reddy’s, Glenmark: Pharma Shares Fall as Centre Bans OTC Cough Syrup Sales

Pharma shares lower June 16. Drugs (Fifth Amendment) Rules 2026 bans OTC cough syrups (notified June 9). Schedule K amended: all syrups now need prescription. Cipla, Sun Pharma, Glenmark impacted.

Pharma shares including Cipla, Sun Pharma, Dr Reddy’s, and Glenmark are trading lower on June 16, 2026, after the Union Ministry of Health and Family Welfare notified the Drugs (Fifth Amendment) Rules, 2026 on June 9, removing the word “Syrups” from Schedule K of the Drugs Rules, 1945. This amendment effectively ends the over-the-counter (OTC) sale of all cough syrups and other liquid medicines in India – consumers must now present a valid doctor’s prescription to purchase any syrup at a pharmacy. The rule change directly impacts branded OTC cough syrup revenues for major pharma shares companies, with Glenmark (Alex Cough Syrup), Cipla (Benadryl), and Sun Pharma having the most visible OTC brand exposure.

Click Here – Get Free Investment Predictions

Pharma Shares Impacted: Companies and Products

The OTC Cough Syrup Rule: What Changed and Why

Pharma Shares Falling: Why the Schedule K Amendment Matters

Schedule K of India’s Drugs Rules, 1945 has historically been a significant commercial enabler for pharma companies selling branded OTC products. The Schedule lists drugs that are exempt from standard drug sale licensing restrictions, allowing items like cough syrups to be sold from general stores, kirana shops, and pharmacies without any prescription requirement. This OTC accessibility was what allowed Benadryl (Cipla), Alex Cough Syrup (Glenmark), and similar branded products to achieve mass-market penetration and consistent repeat-purchase volumes.

The Drugs Fifth Amendment removes “Syrups” from Schedule K, hurting pharma shares, as the government has ended this commercial advantage. All cough syrups – branded or generic – now require a prescription. For pharma shares, this means: (1) spontaneous OTC purchases at pharmacies will stop; (2) retail distribution channel dynamics change as pharmacies must maintain prescription records; (3) branded consumer recall for products like Alex or Benadryl must now be converted to doctor recommendation to sustain volumes. The total OTC cough syrup market in India is estimated at Rs 4,500-5,000 crore annually, representing a meaningful revenue stream for companies with strong branded presence in this category.

Kunal Singal, Associate Director at Univest, notes that the pharma shares sell-off reflects both the immediate revenue headwind and the structural change in the OTC-to-prescription conversion dynamics. Glenmark faces the most direct impact because Alex Cough Syrup is a flagship OTC brand with strong consumer awareness. Cipla’s Benadryl, a well-known pharma shares OTC product, has significant retail market share. The sell-off in pharma shares is likely overdone in the near term for companies like Cipla and Sun Pharma, which have large prescription drug pipelines that can offset the OTC syrup impact. Glenmark, with higher OTC exposure, may see a longer-lasting revenue headwind.

Background: Child Deaths and WHO Alerts Triggered the Rule

The pharma shares pressure today is the culmination of regulatory changes that has been building for over two years. Multiple children died in Madhya Pradesh and Rajasthan after consuming contaminated cough syrups adulterated with toxic chemicals. Separately, WHO issued global health alerts on India-made cough syrups linked to the deaths of over 140 children in Africa and Central Asia since 2022. A WHO alert specifically named Coldrif cough syrup, made by Tamil Nadu-based Sresan Pharmaceuticals, linked to the deaths of more than 20 children.

These incidents prompted the Drugs Controller General of India (DCGI) to intensify inspections of cough syrup manufacturers – with 90% of manufacturers inspected in early 2026 and several found with quality lapses. The Health Ministry’s draft notification in December 2025 – proposing Schedule K amendment – was the formal step toward this rule change, and June 9’s notification converts the proposal into enforceable law. For pharma shares, the rule also signals that the regulatory environment for OTC consumer health products is tightening, with potential for further Schedule K amendments beyond just cough syrups.

Track Cipla, Sun Pharma and pharma sector stocks live on the Univest Screener

Pharma Shares Revenue Impact: OTC to Prescription Shift

For pharma shares investors tracking these OTC rule changes, the key question is how material the revenue impact will be. Historical context for pharma shares is instructive: in 2016, when the government banned over 300 fixed-dose combinations (FDCs) including some cough preparations, Pfizer’s Corex-dependent revenues were significantly impacted, but the overall sector recovered as prescription volumes compensated. The current Schedule K amendment differs from an outright product ban – cough syrups are not banned, they simply require prescriptions. This means: (1) patients who visit doctors will still receive prescriptions for legitimate cough treatment; (2) the reduction in volumes will primarily come from impulse or self-medication purchases that will no longer be possible; (3) companies can invest in doctor detailing to convert OTC volume to prescription volume over 12-24 months.

Ankit Jaiswal, Senior Research Analyst at Univest, estimates the pharma shares OTC impact at 2-4% of domestic branded revenues for companies with significant cough syrup brands. For the broader pharma shares sector – which includes large prescription drug exports and hospital supplies – this headwind is manageable. The sell-off in pharma shares on June 16 should be viewed as a short-term sentiment reaction rather than a fundamental re-rating, unless companies report sustained volume declines in their consumer health segments.

Download the Univest iOS App or Univest Android App to get live pharma share price alerts and sector regulation news in real time.

Conclusion

Pharma shares including Glenmark, Cipla, Sun Pharma and other pharma shares are under pressure on June 16, 2026, following the Centre’s June 9 notification of Drugs (Fifth Amendment) Rules, 2026 removing all syrups from Schedule K’s OTC exemption list. The rule ends over-the-counter cough syrup sales across India, requiring doctor prescriptions for all syrup purchases. Glenmark (Alex Cough Syrup) faces the highest direct exposure; Cipla (Benadryl) has significant but manageable impact. The broader pharma shares outlook remains constructive given prescription drug growth and export pipeline strength. Kunal Singal and Ankit Jaiswal at Univest advise monitoring Q1 FY27 consumer health revenue disclosures from affected pharma shares companies to assess the actual magnitude of the revenue shift.

Frequently Asked Questions

Why are pharma shares falling today?

Ans. Pharma shares including Cipla, Sun Pharma, Dr Reddy’s, and Glenmark are trading lower on June 16, 2026, after the Union Ministry of Health and Family Welfare notified the Drugs (Fifth Amendment) Rules, 2026 on June 9. The amendment removes the word ‘Syrups’ from Schedule K of the Drugs Rules, 1945, effectively ending over-the-counter sale of all cough syrups and other syrups in India. Consumers will now need a valid doctor’s prescription to purchase these products from pharmacies. This rule directly impacts branded OTC cough syrup revenues for major pharma companies.

What is the Drugs Fifth Amendment Rules 2026 and what does it change?

Ans. The Drugs (Fifth Amendment) Rules, 2026 amends the Drugs Rules, 1945 by removing the word ‘Syrups’ from item number 7 under the heading ‘Class of Drugs’ in Schedule K. Schedule K previously listed syrups (along with lozenges, certain tablets, pain balm, antacids, and other items) as medicines that could be sold without a prescription from general stores and pharmacies. By removing syrups from this Schedule K exemption list, the government has effectively ended over-the-counter sale of all syrups – including cough syrups. From June 9, 2026, pharmacies must demand a valid prescription from a registered medical practitioner before dispensing any syrup.

Which pharma companies are most affected by the OTC cough syrup ban?

Ans. The impact varies by company depending on their exposure to OTC cough syrup revenues. Glenmark is most directly impacted because Alex Cough Syrup, its flagship OTC cough product, is a significant revenue contributor in the branded generics segment. Cipla’s Benadryl (a codeine-based cough suppressant) is also a major branded OTC product. Sun Pharma has a range of OTC cough and cold formulations. Among non-listed companies, Pfizer India’s Corex and Abbott India’s Phensedyl are historically the largest branded OTC cough syrups in India. The total OTC cough syrup market in India is estimated at Rs 4,500-5,000 crore annually, approximately 3-5% of revenues for pharma shares companies.

Why did the Centre ban OTC cough syrup sales?

Ans. The Centre’s decision to end over-the-counter cough syrup sales was triggered by two sets of concerns. First, the immediate trigger was contaminated cough syrup deaths among children in Madhya Pradesh and Rajasthan, where adulterated cough syrups containing toxic chemicals caused fatalities. Second, the global context included multiple WHO alerts on India-made cough syrups being linked to the deaths of over 140 children across Africa and Central Asia since 2022, including deaths linked to Coldrif syrup (made by Sresan Pharmaceuticals in Tamil Nadu). The draft notification was issued in December 2025 and the final rule was notified on June 9, 2026, after public comments were received and reviewed.

How much of pharma company revenues come from OTC cough syrups?

Ans. Cough and cold syrups represent approximately 5-8% of domestic branded revenues for major Indian pharma companies. For the Indian pharmaceutical industry as a whole, the respiratory segment (which includes cough syrups) accounts for approximately 17% of domestic prescription and OTC sales. Purely OTC cough syrup volumes are estimated at Rs 4,500-5,000 crore annually across India. For Glenmark, Alex Cough Syrup is among its top OTC brands. For Cipla, Benadryl contributes meaningfully to consumer health revenues. The prescription-only rule will shift some of this OTC volume to prescription-driven sales, not eliminate it entirely – patients who genuinely need cough medicine will still get prescriptions.

Will the OTC cough syrup ban permanently reduce pharma revenues?

Ans. The ban is unlikely to permanently reduce pharma shares revenues by the full OTC volume, but it will change the channel. Under the new rules, patients who previously bought cough syrups OTC will now need a prescription. Some proportion of OTC cough buyers – those with mild, self-limiting coughs – may switch to alternative remedies or simply not purchase a prescription. This is the demand that pharma companies will lose. However, for patients with genuine respiratory conditions who see doctors, prescriptions will still be issued and cough syrups will still be dispensed. The net revenue impact on pharma shares is estimated at 2-3% of affected companies’ domestic revenues, but it is a recurring headwind.

Is there any chance the OTC cough syrup ban will be reversed?

Ans. The Drugs Fifth Amendment – the primary catalyst for pharma shares selling today – has been formally notified in the Official Gazette and came into force on June 9, 2026. This is a legal rule change under the Drugs and Cosmetics Act, 1940, which means it cannot be easily reversed by any state government or pharmacy association. However, pharma companies or trade associations may challenge the rule in court (as Pfizer had done in 2016 during a previous OTC syrup regulation attempt). Courts had previously stayed certain cough syrup regulations. Whether similar challenges will be filed against the June 2026 amendment – which could temporarily reverse the pharma shares selling – remains to be seen. Investors should watch for any court stay orders that could temporarily pause the enforcement of the prescription requirement.

What should pharma investors do given the cough syrup rule change?

Ans. Pharma shares investors should evaluate each company’s exposure to OTC cough syrup revenues individually. Glenmark is most exposed (Alex Cough Syrup is a flagship brand). Cipla has meaningful Benadryl exposure. Sun Pharma and Dr Reddy’s have lower relative OTC syrup exposure compared to prescription segments. The rule change is a headwind for FY27 revenues for pharma shares, but the sector’s diversification across prescription drugs, exports, and hospital sales provides buffer. Pharma shares investors should look for companies that can transition some OTC syrup volumes to prescription channels and have strong prescription drug pipelines to offset the consumer health impact. Always consult a SEBI-registered investment adviser before making investment decisions in pharma shares.